In the second part of our roundup, we review how funds from Luxembourg, the UK and Ireland performed in the third quarter of the year.
Forte Pharma Fund The Luxembourg domiciled Sicav fund aims achieve its objective of generating long-term returns consistent with the preservation of capital, through a strategy focused on structured notes linked to underlyings in the global pharmaceutical and biotechnology sectors. September delivered a positive performance for Forte Pharma Fund, which was up 2.0% – outperforming both MSCI World Index (+0.9%) and MSCI World Pharmaceuticals, Biotechnology & Life Sciences Index (-4.7%)